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We report on a breast carcinoma with medullary features diagnosed by core nee-
dle biopsy in a 72-year-old woman. Both the primary tumour and its fine needle 
aspiration-proven, rapidly growing axillary metastasis regressed completely in 
less than 2 months, by the time surgery was performed. The biopsy of the pri-
mary tumour demonstrated a dense stromal infiltrate of CD8+/granzyme B+ 
activated cytotoxic T-cells suggestive of a robust antitumour immune response. 
Paradoxically, both tumour cells and tumour infiltrating immune cells demon-
strated a diffuse PD-L1 expression, revealing that antitumour immune response 
has the ability to spontaneously overcome inhibitory mechanisms induced by 
cancerous growth. 
Key words: PD-L1, spontaneous regression, tumour-infiltrating lymphocytes, 
triple-negative breast cancer.
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Introduction
Spontaneous regression of malignant tumours is de-
fined as the disappearance of cancer without any therapy 
given or following a treatment that is considered inad-
equate to cure this disease. It is a rare event, estimated 
to occur in 1 out of 60,000 to 100,000 cases [1], and is 
more common in some types of tumours (e.g. melanoma) 
than others. Breast cancer regression was reported in 
43/741 cases of spontaneously regressing cancers com-
piled and summarized by Challis and Stam reviewing 
the period of 1900-1987 [2], and only a few additional 
reports have been published since [3 4, 5, 6, 7]. Several 
mechanisms have been implicated, but most authors as-
sociate spontaneous regression with variously activated 
antitumour immunity [2]. Here, we report on a biopsy-
proven breast cancer with axillary metastasis that sponta-
neously regressed completely in less than 2 months.
Case report
A 72-year-old obese female with type 2 diabetes and 
hypertension was recalled after attending an opportunistic 
screening mammography (day 0 of her presented history; 
Fig. 1A). She appeared 27 days later, when her right breast 
was perceived as having a 7-mm circumscribed nonpal-
pable benign lesion with microcalcification in the upper-
outer quadrant at the 10 o’clock position, with a physi-
cally negative ipsilateral axilla, which on ultrasound (US) 
showed an enlarged lymph node (13 × 8 mm) with a thick-
ened cortical layer. In contrast, the upper-outer quadrant 
of her left breast harboured an ill-defined, spiculated 
mass with microcalcification (Fig. 1B); this corresponded 
to a firm mobile palpable mass measuring 16 mm in the 
greatest dimension on US, located in the two o’clock posi-
tion, 2 cm from the areola and 6 mm deep from the skin. 
The left axilla demonstrated a rounded pathological lymph 
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node, which was not present on the screening mammo-
gram (Fig. 1B); this measured 34 × 25 mm on US. 14G 
needle core biopsy was obtained from the left sided prima-
ry tumour, and this resulted in a grade 3 (poorly differen-
tiated) carcinoma with medullary features, also classified 
as lymphocyte predominant breast cancer with over 60% 
stromal mononuclear cells [8] (Fig. 2A). The phenotype 
was triple-negative, i.e. the tumour cells were negative for 
oestrogen receptors (ER), progesterone receptors (PR), 
and human epidermal growth factor receptor-2 (HER2), 
but showed cytokeratin 5 staining and high (about 60%) 
Ki-67/MIB1 labelling on immunohistochemistry. US-
guided fine needle aspiration cytology was done on both 
axillary lymph nodes described, yielding a negative result 
on the right side and proving metastatic involvement on 
the left side (Fig. 2B). Magnetic resonance imaging of the 
breasts could not be performed due to the patient being 
oversized for the machine. On the basis of a multidiscipli-
nary team decision, the right sided breast lesion was also 
targeted with US-guided core needle biopsy on day 40; 
this resulted in an invasive carcinoma diagnosis (luminal 
A-like no special type carcinoma, grade X – ungradable 
due to limited amount of material, but non-high grade; ER 
and PR highly expressed, HER2-negative, CK5-negative, 
Ki-67/MIB1 labelling of around 10%, Table I). Perform-
ance of bilateral radio-guided and wire-guided wide local 
excisions plus right sided sentinel lymph node biopsy and 
left sided axillary lymph node dissection were decided; 
these were done on day 83 of the presented medical his-
tory, 56 days after the left sided biopsies. The left sided 
lesion was not easy to localise preoperatively (Fig. 1C), 
but the critical area was confirmed to be removed by speci-
men mammography (Fig. 1D). The 82-g, dominantly fatty 
specimen included a 14 × 11-mm tumour bed with no re-
Fig. 1. The figure demonstrates different time points of the case history on single-view left side mammography. 
A) The screening medio-lateral-oblique (MLO) view at time 0 shows the primary tumour in the upper-outer quadrant. 
B) After recall, on day 27, the MLO view shows the tumour in the same location with a newly identified axillary me-
tastasis. C) On day 83, before the introduction of the localising hooked wire, the tumour site and the metastasis are 
less evident on the ML view. D) The specimen mammogram shows the wire guided removal of the primary tumour 
site. E) The MLO view of the operated left breast on day 131 shows the clips in the tumour bed area, with no evidence 
of residual disease or calcification
Table I. The table shows the antibodies used and there sources, dilutions used in the analysis
antibody 6f11 sourCe dilution
ER PgR3112 Leica-Novocasta 1:400
PR 4B5 Leica-Novocastra 1:200
HER2 DO7 Roche-Ventana RTU
p53 XM26 Leica-Novocastra RTU
CK5 MIB1 Thermo-Fisher 1:20
Ki67 22c3 Dako-Agilent 1:100
PD-L1 NAT105 Dako-Agilent 1:40
PD1 11F1 Abcam 1:50
Granzyme B polyclonal Leica-Novocastra 1:100
CD3 1A5 Dako-Agilent RTU
CD8 Frequent Biocare 1:150
DBA C E
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sidual carcinoma, but wavy loose fibrotic tissue, and focal 
aggregates of lymphocytes and calcifications (Fig. 2C). 
No lymph node metastases were detected, but two lymph 
nodes also demonstrated signs of regression with a similar 
wavy loose fibrous tissue (Fig. 2D). Although radio-path-
ological correlation was present, a repeated breast imaging 
was performed on day 131; it showed a postoperative sta-
tus with clips in the excision area, but no signs of residual 
disease (Fig. 1E). The whole excised breast was investi-
gated histologically, and this showed no residual invasive 
tumour or tumour bed; however, a low-grade (well-differ-
entiated), ER-positive, HER2-negative, and CK5-negative 
solid and cribriform ductal carcinoma in situ (DCIS) of 
8 mm greatest dimension was found away from the tu-
mour bed. We obtained a careful history of the patient. 
There have been no changes in food, nor in drugs taken 
for her diabetes and hypertension. Metformin (1000 mg 
twice daily), an antidiabetic with reported antitumor activ-
ity [9] had been part of her treatment for many years, she 
was taking it before the diagnosis of breast cancer, during 
its fast nodal progression (Fig. 1A, B) and its regression 
(Fig. 1B, C). Spontaneous regression of the grade 3 carci-
noma and its axillary metastases was established, and the 
ipsilateral DCIS identified was considered an incidentally 
identified different disease. The right sided carcinoma cor-
responded to a 5-mm carcinoma of no special type, and 
its single sentinel node was free of metastasis. Adjuvant 
aromatase inhibitor treatment was initiated.
Fig. 1. The figure shows different microscopical aspects of the primary tumour (bed) and its nodal metastasis (bed). 
A) Detail of the core needle biopsy of the primary tumour shows a lymphocyte rich stroma and pleomorphic tumour 
cells (HE, 60×; Insert: CK5 immunostaining, 40×). B) The fine needle aspirate from the metastatic lymph node shows 
tumour cells and smaller lymphocytes (Papanicolaou, 60×). C) The operative specimen showed a tumour bed empty of 
tumour cells, but with foci a lymphoid aggregates (HE, 60×). D) The lymph node also shows complete regression with 
fibrous transformation (HE, 60×). E) The CD3 reaction highlights that the majority of the stromal lymphocytes are 
T-cells (CD3, 60×). F) The dense lymphoid infiltrate is composed of CD8-positive T-cells (CD8, 60×). G) The high-
power granzyme-B immunostain illustrates the close contact of activated cytotoxic (killer) T-cells with a tumour cell 
with the apoptosis of the latter (arrow; Granzyme-B, 100×). H) The tumour biopsy demonstrates intense and diffuse 
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Histological re-appraisal of the primary tumour sample 
of the regressed carcinoma demonstrated dense peritumor-
al and intratumoural stromal lymphocytic infiltrate giving 
the impression that virtually every tumour cell was in di-
rect physical contact with lymphocytes (Fig. 2A, E-H). 
These lymphocytes were predominantly CD8+/granzyme 
B+ activated cytotoxic T-cells, and scattered apoptotic tu-
mour cells could also be appreciated (Fig. 2G). Further-
more, the sample demonstrated diffuse programmed cell 
death ligand 1 (PD-L1) expression in tumour cells and in-
filtrating immune cells (Fig. 2H), while programmed cell 
death (PD1) molecules showed up to 50% positivity rate 
restricted to the infiltrating lymphocytes. 
Discussion
Spontaneous regression of breast cancer is a rare 
event, and although recognised in the medical literature, 
it is still a surprising phenomenon. With current interest 
in antitumour immunity and its stimulation with immu-
notherapy and immune checkpoint inhibitors, these cases 
might deserve special attention. 
Due to the rarity of the phenomenon of spontaneous 
regression, case reports and their compilations only col-
lect possible explanations, and the study of the reported 
single cases is restricted by the lack of sufficient data 
on a number of newly introduced biomarkers. Immune 
mechanisms are the most commonly mentioned possible 
cause of cancer regression, but infectious, hormonal, op-
erative trauma-related, ischaemia/necrosis-related factors 
have all been mentioned in the literature [2].
Even the rare case reports on spontaneously regressive 
breast cancer are heterogeneous: they include partial or 
nearly complete regression [4, 5], and complete regres-
sion cases [3, 4]. The preoperative diagnosis of sponta-
neously regressive breast cancers is also variable, some 
rely on fine needle aspirates only [5, 7], and a few have 
a tissue diagnosis by core needle biopsy [3, 6], allowing 
the assessment of the lymphoid component at diagnosis. 
The postoperative assessment either showed necrosis 
with inflammatory cells [5] or, as in the presented case, 
a fibrotic tumour bed with inflammatory cells [7]. The 
phenotype of the tumours has been rarely reported, but it 
seems that oestrogen receptor-positive carcinomas have 
also regressed spontaneously [5], or on corticosteroid 
alone [4], although the phenomenon might be more com-
mon in triple-negative carcinomas [6] or oestrogen and 
progesterone receptor negative carcinomas when HER2 
was not tested [3]. Our spontaneously regressive case 
seems to represent a basal-like carcinoma on the basis 
of the triple-negative phenotype, and diffuse CK5 and 
p53 expression [10]. In keeping with the presented his-
tory, medullary carcinomas (generally triple-negative in 
phenotype) had better prognosis than carcinomas of no 
special type of the same grade, and medullary carcino-
mas with greater amount of lymphoid stroma had better 
survival than those with fewer mononuclear cells [11], 
pointing to the role tumour infiltrating lymphocytes may 
play in antitumour defence.
Both CD4- and CD8-positive subsets of CD3-positive 
T-cells have been implicated in the genesis of sponta-
neous regression [5], although natural killer cells were 
also suggested in another case [4]. The initiation might 
be related to the biopsy trauma, as suggested by Maillet 
et al. [6]. Our findings suggest a robust antitumour im-
mune response mediated by activated cytotoxic (killer) 
T-cells. To the best of our knowledge, our report is the 
first that reveals strong and diffuse tumoural expression of 
PD-L1 in spontaneously regressive breast cancer, a mol-
ecule that may play a major role in tumour-associated 
T-cell inhibitory mechanisms [12]. One could assume that 
such a PD-L1 expression is contrary to spontaneous re-
gression because high PD-L1 expression was found to be 
associated with poor prognosis [13], but this phenomenon 
may suggest that the antitumour immune response has the 
ability to spontaneously overcome inhibitory mechanisms 
induced by cancerous growth. Our finding of strong and 
diffuse PD-L1 expression is in keeping with the results 
obtained on a relatively large tissue microarray study as-
sociating PD-L1 expression with oestrogen receptor nega-
tivity, progesterone receptor negativity, high histological 
grade, high Ki67 labelling, and high numbers of tumour 
infiltrating lymphocytes, CK5 expression, and p53 expres-
sion [14]. High PD-L1 labelling is relatively common in 
triple-negative breast carcinomas, and a better prognosis 
has been associated with lymphocyte predominant breast 
carcinomas showing high PD-L1 expression [14], which 
is also in line with the reported case. However, it remains 
elusive how the presented tumour managed to overcome 
the PD-L1 – PD1 axis spontaneously because the results 
quoted in the previous sentence were gained from tumours 
of patients who received systemic treatment. The potential 
role of metformin was considered unlikely due to the drug 
having been taken even before the progressive phase of 
the regressing carcinoma.
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